Telomir Pharmaceuticals (NASDAQ:TELO) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Telomir Pharmaceuticals (NASDAQ:TELO) announced its quarterly earnings data on Monday. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04, Zacks reports.

Telomir Pharmaceuticals Price Performance

Shares of TELO traded up $0.06 during mid-day trading on Monday, reaching $1.37. 203,759 shares of the company’s stock traded hands, compared to its average volume of 1,898,730. Telomir Pharmaceuticals has a 12 month low of $1.12 and a 12 month high of $7.08. The stock has a market cap of $44.22 million, a P/E ratio of -2.54 and a beta of -0.54. The stock’s 50-day moving average is $1.45 and its two-hundred day moving average is $1.73.

Institutional Trading of Telomir Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of TELO. Jane Street Group LLC purchased a new position in Telomir Pharmaceuticals in the 2nd quarter worth approximately $62,000. Qube Research & Technologies Ltd acquired a new stake in shares of Telomir Pharmaceuticals in the 2nd quarter valued at approximately $33,000. Marshall Wace LLP purchased a new stake in Telomir Pharmaceuticals during the second quarter worth $95,000. Finally, Bank of America Corp DE increased its position in Telomir Pharmaceuticals by 283.9% during the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock worth $61,000 after buying an additional 10,880 shares in the last quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.